CS Stock Analysis: AXA | PA

Insurance - Diversified | PA, France | Market Cap: 88.306m EUR | 12M Return: 11.9% | Charts, Fundamentals & Technical Analysis

Life Insurance, Property Casualty, Asset Management, Health Insurance
Total Rating 41
Safety 17
Buy Signal 0.05
Insurance - Diversified
Industry Rotation: +6.5
Market Cap: 101B
Avg Turnover: 144M
Risk 3d forecast
Volatility16.0%
VaR 5th Pctl2.96%
VaR vs Median12.6%
Reward TTM
Sharpe Ratio0.38
Rel. Str. IBD55.2
Rel. Str. Peer Group60.5
Character TTM
Beta0.027
Beta Downside-0.346
Hurst Exponent0.568
Drawdowns 3y
Max DD13.69%
CAGR/Max DD1.72
CAGR/Mean DD5.61

Warnings

Volatile

Tailwinds

Supp Ema8

Seasonality 10.5 years of data

Jan +3.2% 14
Feb +0.2% 13
Mar +1.5% 0
Apr +1.8% 41
May -0.4% 13
Jun -1.3% 14
Jul +0.7% 0
Aug +0.1% 0
Sep -0.9% 26
Oct -2.6% 30
Nov +0.4% 0
Dec +0.8% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CS AXA

AXA SA is a Paris-based global financial services group founded in 1852 that provides insurance, asset management, and banking services across six operating segments: France, Europe, AXA XL, Asia, Africa & EME-LATAM, and Transversal & Other. As a multi-line insurer, AXA generates revenue through a mix of insurance premiums, investment income on policyholder reserves, and fee-based businesses, which helps diversify earnings across life and non-life cycles.

The companys core offerings span life and savings insurance, property and casualty insurance, and protection and retirement products for individual and professional customers. Distribution extends to both retail/individual and commercial/group channels, with products including motor, household, health, term and whole life, universal life, endowments, and annuities.

AXA runs an extensive reinsurance operation through its AXA XL segment, covering casualty, property catastrophe, marine, aviation, energy, environmental liability, professional liability, and specialty lines via proportional, non-proportional, and facultative treaties. Reinsurance acts as both a standalone product and an internal tool to manage underwriting volatility.

The group has built digital and healthcare-adjacent services, including Sophia (a generative AI customer chatbot), EMMA (a digital assistant), the AXA Multilink B2B2C platform, and an integrated health ecosystem combining teleconsultation, in-clinic, and home-care services with insurance coverage. Travel insurance and assistance round out the offering.

Headlines to Watch Out For
  • Life and savings margins expand on higher interest rate environment
  • AXA XL reinsurance combined ratio pressured by elevated catastrophe losses
  • Share buybacks accelerate as Solvency II ratio remains robust
Piotroski VR-10 (Strict) 6.0
Net Income: 9.80b TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.55 > 1.0
NWC/Revenue: -538.8% < 20% (prev 402.6%; Δ -941.3% < -1%)
CFO/TA 0.03 > 3% & CFO 21.5b > Net Income 9.80b
Net Debt (39.6b) to EBITDA (10.1b): 3.91 < 3
Current Ratio: 0.10 > 1.5 & < 3
Outstanding Shares: last quarter (2.03b) vs 12m ago -8.98% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 12.49% > 50% (prev 12.51%; Δ -0.02% > 0%)
Interest Coverage Ratio: 17.33 > 6 (EBIT TTM 10.9b / Interest Expense TTM 627.0m)
Altman Z'' -4.08
A: -0.68 (Total Current Assets 46.1b - Total Current Liabilities 480b) / Total Assets 636b
B: 0.07 (Retained Earnings 41.4b / Total Assets 636b)
C: 0.02 (EBIT TTM 10.9b / Avg Total Assets 645b)
D: 0.07 (Book Value of Equity 42.6b / Total Liabilities 586b)
Altman-Z'' = -4.08 = D
Beneish M -1.50
DSRI: 2.45 (Receivables 23.9b/9.90b, Revenue 80.5b/81.8b)
GMI: 0.75 (GM 102.3% / 135.6%)
AQI: 1.96 (AQ_t 0.92 / AQ_t-1 0.47)
SGI: 0.98 (Revenue 80.5b / 81.8b)
TATA: -0.02 (NI 9.80b - CFO 21.5b) / TA 636b)
Beneish M = -1.50 (Cap -4..+1) = D
What is the price of CS shares?

As of July 04, 2026, the stock is trading at EUR 43.71 with a total of 1,559,635 shares traded. Over the past week, the price has changed by +0.69%, over one month by +11.99%, over three months by +14.87% and over the past year by +11.91%.

Current recommended Stop Loss: 42.10 (which is 3.7% or 2.6 ATR below the current price).

Is CS a buy, sell or hold?

AXA has no consensus analysts rating.

AXA (CS) - Fundamental Data Overview as of 29 June 2026
Market Cap USD = 101b (88.3b EUR * 1.1421 EUR.USD)
P/E Trailing = 12.693
P/E Forward = 10.4822
P/S = 0.9326
P/B = 1.872
P/EG = 1.2122
Revenue TTM = 80.5b EUR
EBIT TTM = 10.9b EUR
EBITDA TTM = 10.1b EUR
Long Term Debt = 60.5b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.78b EUR (from shortTermDebt, last fiscal year)
Debt = 61.9b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.6b EUR (calculated: Debt 61.9b - CCE 22.2b)
Enterprise Value = 128b EUR (88.3b + Debt 61.9b - CCE 22.2b)
Interest Coverage Ratio = 17.33 (Ebit TTM 10.9b / Interest Expense TTM 627.0m)
EV/FCF = 6.08x (Enterprise Value 128b / FCF TTM 21.1b)
FCF Yield = 16.46% (FCF TTM 21.1b / Enterprise Value 128b)
FCF Margin = 26.14% (FCF TTM 21.1b / Revenue TTM 80.5b)
Net Margin = 12.16% (Net Income TTM 9.80b / Revenue TTM 80.5b)
 Gross Margin = unknown ((Revenue TTM 80.5b - Cost of Revenue TTM -28.7b) / Revenue TTM)
 Tobins Q-Ratio = 0.20 (Enterprise Value 128b / Total Assets 636b)
Interest Expense / Debt = 1.01% (Interest Expense 627.0m / Debt 61.9b)
Taxrate = 23.67% (2.37b / 10.00b)
NOPAT = 8.29b (EBIT 10.9b * (1 - 23.67%))
Current Ratio = 0.10 (Total Current Assets 46.1b / Total Current Liabilities 480b)
Debt / Equity = 1.45 (Debt 61.9b / totalStockholderEquity, last quarter 42.6b)
Debt / EBITDA = 3.91 (Net Debt 39.6b / EBITDA 10.1b)
Debt / FCF = 1.88 (Net Debt 39.6b / FCF TTM 21.1b)
Total Stockholder Equity = 44.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.52% (Net Income 9.80b / Total Assets 636b)
RoE = 21.83% (Net Income TTM 9.80b / Total Stockholder Equity 44.9b)
RoCE = 10.31% (EBIT 10.9b / Capital Employed (Equity 44.9b + L.T.Debt 60.5b))
RoIC = 5.47% (NOPAT 8.29b / Invested Capital 151b)
WACC = 3.89% (E(88.3b)/V(150b) * Re(6.08%) + D(61.9b)/V(150b) * Rd(1.01%) * (1-Tc(0.24)))
Discount Rate = 6.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.22 | Cagr: -6.97%
[DCF] Terminal Value 77.97% ; FCFF base≈17.3b ; Y1≈19.8b ; Y5≈29.1b
[DCF] Fair Price = 195.8 (EV 438b - Net Debt 39.6b = Equity 398b / Shares 2.03b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.81 | EPS CAGR: 18.42% | SUE: 0.0 | # QB: 0
Revenue Correlation: -44.21 | Revenue CAGR: -8.45% | SUE: 0.00 | # QB: 0
EPS current Year (2026-12-31): EPS=4.12 | Chg30d=+0.12% | Revisions=-30% | GrowthEPS=+6.8% | GrowthRev=+25.4%
EPS next Year (2027-12-31): EPS=4.45 | Chg30d=+0.03% | Revisions=+0% | GrowthEPS=+8.0% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -19% (up=5, down=8)